Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, November 11, 2011 - Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) today announced the receipt of a letter from the U.S. Food and Drug Administration (FDA) indicating that it accepted...
Read more about Receipt of Filing Communication Letter from U.S. FDA Regarding Mirabegron (YM178)
Astellas Pharma Inc. (Headquarters, Tokyo; President & CEO, Yoshihiko Hatanaka) today announced that the administration of the recombinant influenza HA vaccine (H5N1) ASP7373 (former code:...
Tokyo, Japan, November 11, 2011 - Astellas Pharma Inc. (Tokyo:4503,“Astellas”) announced today that it is signing the United Nations Global Compact1, which will further reinforce the...
Read more about Astellas Signs United Nations Global Compact
Tokyo, Japan, October 28, 2011 – The Astellas Asia-Oceania Foundation announced that it will make a donation of USD $20,000 to the Thai Red Cross Society to assist with relief efforts after the...
Read more about The Astellas Asia-Oceania Foundation Supports Thai Flood Relief Efforts
Tokyo, Japan, October 17, 2011 - Astellas Pharma Inc. (Tokyo:4503,“Astellas”) announced that the Societe Internationale d’Urologie (SIU) presented its senior science advisor (and former...
Read more about Astellas' Senior Science Advisor Receives "Distinguished Partner Award" from SIU
Follow us
